Different efficacy results for the Sinopharm COVID-19 vaccine were both “real and valid”, according to CNBG executive
An executive at China National Biotec Group (CNBG) told state media that different efficacy results for the Sinopharm COVID-19 vaccine were both “real and valid”.
This, as China on Thursday approved Sinopharm COVID-19 vaccine for general public use after the developer said that the COVID-19 vaccine showed 79.34 percent efficacy based on an interim analysis of late-stage human clinical trials.
The said efficacy rate was lower than the 86 percent efficacy rate for the same vaccine reported by the United Arab Emirates last December 9, 2020.
Yang Xiaoming, the chairman at Sinopharm unit’s CNBG, told Global Times that countries had certain differences in their standards and procedures in diagnosing patients, adding that the final results of COVID-19 case identification were different.
“Therefore, there were differences between the comprehensive multi-country data we reviewed and the protection rate data previously evaluated by the UAE and Bahrain,” Global Times quoted Yang Xiaoming as saying in a report published last Thursday.
However, Yang said that efficacy results for Sinopharm COVID-19 vaccine in China and UAE were “both real and valid”.
READ ALSO: Sinopharm Vaccine Distributor Denies Involvement In PSG COVID-19 Inoculation
Yang also said that CNBG didn’t participate in the review or analysis of human clinical trial data released by regulators in countries wherein the Sinopharm COVID-19 vaccine was being trialed.
The said vaccine — along with another vaccine candidate from CNBG’s Wuhan-based unit — was being tested in Phase 3 human clinical trials outside China.
Moreover, Yang said that trials for CNBG’s candidates had recruited more than 60,000 participants aged between 18 to 60 years old.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via the official Facebook page and YouTube channel.
